Introduction
Apoptosis, a form of programmed cell death, is a program of cellular suicide critical for both proper embryonic development and homeostasis of adult tissues (Danial and Korsmeyer, 2004) . The apoptotic program is executed by a family of highly conserved proteases known as caspases, which dismantle the cell in an orderly fashion by cleaving a large number of cellular substrates. Aberrant caspase regulation has been unequivocally linked to the pathogenesis of a variety of diseases, including various neurological disorders and cancers (Riedl and Shi, 2004) .
Signaling pathways leading to caspase activation are characterized as either extrinsic or intrinsic (summarized in Figure 1 ). The extrinsic pathway involves the binding of extracellular ligands (e.g., FasL) to cell surface receptors (e.g., Fas), resulting in the recruitment of cytosolic adaptor proteins (e.g., FADD), the activation of initiator caspases (e.g., pro-caspase-8), and the subsequent activation of downstream effector caspases (Nagata, 1999) . More germane to this review, proapoptotic signals transmitted via the intrinsic pathway converge on the mitochondria, resulting in outer membrane permeablization and the subsequent release of cytochrome c (a component of the electron transport chain) and other proapoptotic molecules into the cytosol (Green and Kroemer, 2004; Olson and Kornbluth, 2001 ). This process of mitochondrial cytochrome c release is intricately regulated by the Bcl-2 family of proteins, which can both promote (e.g., Bax, Bak) or impede (e.g., Bcl-2, Bcl-X L ) cytochrome c release (Cory and Adams, 2002) . In the vast majority of cell types, cytosolic cytochrome c is highly proapoptotic, stimulating caspase activation by forming a large complex with a protein called Apaf-1 and an initiator caspase, pro-caspase-9. This structure, known as the apoptosome, then activates downstream effector caspases, eventually leading to apoptosis (Liu et al., 1996; Srinivasula et al., 1998; Zou et al., 1997) .
Although particular apoptotic signals may stimulate either the extrinsic or intrinsic pathway, crosstalk between these pathways occurs through an initiator caspase engaged by the extrinsic pathway, caspase-8, which can cleave and activate the proapoptotic Bcl-2 family member Bid to promote mitochondrial cytochrome c release (Danial and Korsmeyer, 2004) . The regulation of the intrinsic apoptotic program has been studied extensively, with the great majority of research focused on regulation of Bcl-2 family members and mitochondrial cytochrome c release. However, the discovery of X-linked inhibitor of apoptosis (XIAP), which binds to and directly inhibits the enzymatic activity of caspases, demonstrated that apoptotic regulation can also occur downstream of mitochondrial cytochrome c release (Salvesen and Duckett, 2002) . More recently, many reports have established the apoptosome as a critical locus of apoptotic control, impinged upon by multiple signaling pathways. We will discuss here the emerging importance of the apoptosome and its regulation in physiological, developmental, and pathological contexts.
Formation of the Apoptosome
The Vertebrate Apoptosome Inhibiting apoptosome formation or function can halt transmission of an apoptotic signal along the intrinsic pathway. Conversely, enhancing the apoptosome can boost the efficiency of apoptosis. In vertebrate cells, apoptosome formation is initiated by the release of mitochondrial cytochrome c (summarized in Figure 2 ). The cytochrome c binding partner, Apaf-1, exists in the cytosol as an inactive monomer with three functional domains: an N-terminal caspase recruitment domain (CARD), a central region for nucleotide binding that is homologous to CED-4 (discussed below), and a C-terminal domain composed of multiple WD-40 repeats . It is believed that cytosolic Apaf-1 lacking bound cytochrome c exists in an inactive form, and that the C-terminal domain acts as an autoinhibitor through intramolecular contact with the N-terminal region of the protein. Once cytochrome c binds to the C-terminal domain, it induces a conformational change that permits its activation. In the presence of the nucleotide dATP, the Apaf-1/cytochrome c complex oligomerizes into a heptameric structure resembling a wheel whose core contains seven N-terminal CARDs (Acehan et al., 2002; Adrain et al., 1999; Srinivasula et al., 1998) . The formation of this complex allows interaction of pro-caspase-9 with Apaf-1 through the interaction of its own CARD with the CARD of Apaf-1, thus placing individual pro-caspase-9 molecules in close proximity with one another and promoting their activation (Acehan et al., 2002; Boatright et al., 2003; Yu et al., 2005) . It has recently been verified that this activation of caspase-9 on the apoptosome occurs via dimerization (Pop et al., 2006) . Interestingly, as determined by the crystal structure of the caspase-9 dimer, only one of the two subunits in the dimer is catalytically active (Boatright et al., 2003) . Active caspase-9 can then cleave and activate pro-caspase-3 and pro-caspase-7 to execute the cell death program (Li et al., 1997) . Interestingly, the ability of caspase-9 to efficiently activate caspase-3 has just been reported to depend on an enhanced affinity of caspase-9 for caspase-3 that only occurs after recruitment of caspase-9 to the apoptosome (Yin et al., 2006) .
It should be noted that modification of cytochrome c itself plays a role in apoptosome activation. Cytochrome c is synthesized in its apo form (without a heme group) and is imported into the mitochondria, where heme lyase can catalyze the addition of heme to produce holo-cytochrome c (which is released from the mitochondria during apoptosis). Although apo-cytochrome c is competent to bind Apaf-1, it fails to induce caspase activation and Apaf-1 oligomerization (Martin and Fearnhead, 2002; Martin et al., 2004) . Interestingly, cytochrome c has been shown to be nitrosylated within the mitochondria on its heme group, and inhibition of cytochrome c nitrosylation can diminish its capacity to activate caspases (Schonhoff et al., 2003) . Furthermore, The activation of caspases during apoptosis proceeds through two distinct mechanisms. Activation of caspases through the extrinsic pathway involves the binding of extracellular ligands (e.g., FasL) to their cognate receptors (e.g., Fas) and the recruitment of intracellular adaptor proteins (e.g., FADD) to activate caspase-8 and subsequent downstream effector caspases. The intrinsic pathway involves the release of cytochrome c from the mitochondria into the cytosol. This leads to the formation of the apoptosome, the activation of caspase-9, and the cleavage of effector caspases. Apaf-1 exists in the cytosol as an inactive monomer prior to cytochrome c release from the mitochondria. After release, cytochrome c binds to Apaf-1, induces its conformational change, and allows for dATP hydrolysis. Apaf-1 subsequently oligomerizes into a heptameric structure; caspases and IAPs are then recruited to the complex. cytochrome c may be sensitive to the cellular redox state, as treatment of cytochrome c with reducing agents abolishes its ability to activate caspases (Schonhoff et al., 2003; Suto et al., 2005) .
Although the biochemistry of apoptosome formation has been reconstituted by using purified components in vitro, an understanding of the composition of the native apoptosome in apoptotic cells has emerged only recently. The successful immunoprecipitation of catalytically active apoptosomes from Jurkat cells has revealed that the native apoptosome (at least in this cell type) contains caspase-3 and XIAP in addition to Apaf-1 and caspase-9 (Hill et al., 2004) . This study also intimates that the interaction of XIAP with caspase-9 is necessary for caspase-3 association with the apoptosome. Interestingly, it has been suggested that Smac or Omi/HtrA2, which are coordinately released from the mitochondrial intermembrane space with cytochrome c, may displace XIAP from the apoptosome and thereby increase apoptosomal activity (Twiddy et al., 2004) . These findings raise the intriguing possibility that despite its ability to inhibit caspases, XIAP may initially recruit caspase-3 to the apoptosome, with subsequent displacement of XIAP by Smac or Omi leading to full apoptosomal activation.
The precise role of the nucleotide dATP in apoptosome formation has, until recently, been somewhat mysterious. However, recent work by Xiaodong Wang and colleagues demonstrates that dATP exists as a cofactor with monomeric Apaf-1, is hydrolyzed to dADP upon activation with cytochrome c, and is subsequently exchanged for exogenous dATP to generate the active apoptosome (Kim et al., 2005) . Interestingly, if the concentration of cellular dATP is insufficient for nucleotide exchange after hydrolysis, Apaf-1 will oligomerize into an inactive apoptosome that lacks the capacity to activate caspase-9. In addition, the structure of a C-terminally truncated (lacking the inhibitory WD-40 repeats and hence constitutively active) Apaf-1 has been elucidated and was found to be bound to hydrolyzed nucleotide, providing additional evidence that nucleotide hydrolysis is integral to the formation of a functional apoptosome . Evolution of the Apoptosome Caspase-activating apoptosomes are not unique to vertebrates, though the ways in which apoptosomes are regulated have undergone significant change over evolutionary time. Although proteins distantly related to caspases exist in single-celled eukaryotes, there is no evidence for an apoptosome in unicellular organisms. Some of the most intensively studied apoptosomes are found in invertebrates. Indeed, the first characterized apoptosome components were identified in the nematode Caenorhabditis elegans, an organism whose highly tractable genetics have been used to advance the study of apoptotic regulatory pathways (Metzstein et al., 1998) . A core pathway involving four proteins (CED-3, CED-4, CED-9, and EGL-1) controls apoptosis during C. elegans development. CED-3, the founding member of the caspase family, is a zymogenic protease activated by the adaptor protein CED-4, which bears structural similarity to mammalian Apaf-1, though lacks the autoinhibitory WD-40 repeats (Chinnaiyan et al., 1997; Irmler et al., 1997; Seshagiri and Miller, 1997; Wu et al., 1997; Yang et al., 1998; Yuan and Horvitz, 1992) . Rather, in the absence of an apoptotic stimulus, CED-4 is sequestered from CED-3 through an interaction with the protein CED-9, which is tethered to the mitochondria Chinnaiyan et al., 1997; Hengartner and Horvitz, 1994; James et al., 1997; Spector et al., 1997; Wu et al., 1997) . Although CED-9 has sequence homology to antiapoptotic Bcl-2 family members (and Bcl-2 can complement C. elegans CED-9 mutants), the paradigm of direct apoptosomal regulation by Bcl-2 family members does not appear to extend to vertebrates, where these proteins act upstream to regulate mitochondrial cytochrome c release. In the worm, cells fated to die induce apoptosis through the transcriptional upregulation of EGL-1 (which shares weak sequence homology with proapoptotic Bcl-2 family members), whose role is to disrupt the interaction of CED-9 and CED-4, thereby allowing CED-4 to activate CED-3 (Conradt and Horvitz, 1998; del Peso et al., 1998 del Peso et al., , 2000 Parrish et al., 2000) . The C. elegans apoptosome appears to be tetrameric, rather than heptameric, as in vertebrate cells, and seems to lack detectable ATPase or dATPase activity (Yan et al., 2005) . Although the mitochondria may be involved in regulating formation of the C. elegans apoptosome (by providing a site for CED-9-mediated sequestration of CED-4), there is no compelling evidence that release of proteins from the mitochondria (e.g., cytochrome c) affects formation of the C. elegans apoptosome. However, a recent study has demonstrated that Drp-1, a component of the mitochondrial fission machinery, is involved in the promotion of both mitochondrial fragmentation and caspasedependent cell death in C. elegans (Jagasia et al., 2005) . Moreover, CED-9 and EGL-1 act in opposition to promote or inhibit mitochondrial fragmentation, respectively. This is particularly provocative, as mammalian Drp-1 has been implicated in both mitochondrial fission and cytochrome c release in mammalian cells and the proapoptotic Bcl-2 protein Bax can promote mitochondrial fission (Frank et al., 2001; Karbowski et al., 2002) .
Genome sequencing has allowed for the identification of apoptosomal components in a number of invertebrates besides the worm. Based on such sequence analyses, the Drosophila melanogaster protein Dark/ Hac-1/Dapaf-1 was identified as a potential homolog of mammalian Apaf-1 (Kanuka et al., 1999; Rodriguez et al., 1999; Zhou et al., 1999; Zimmermann et al., 2002) . Like its worm and vertebrate counterparts, Dark serves as an adaptor molecule to promote oligomerization and activation of Dronc, a zymogenic caspase that acts in a capacity similar to mammalian caspase-9 (Chew et al., 2004; Quinn et al., 2000) . Dronc activation promotes cleavage of DrICE, another pro-caspase that is responsible, in part, for the subsequent execution of the apoptotic program . New structural evidence suggests that the D. melanogaster apoptosome exists as a ''double apoptosome'' with two octameric rings lying face to face, and that formation of this structure requires the nucleotide dATP (Yu et al., 2006) .
Although Dark (like Apaf-1) has an N-terminal CARD, a central domain with homology to CED-4, and a C-terminal domain with multiple WD-40 repeats (the domain responsible for the autoinhibition of Apaf-1), the question of whether Dark requires any activating stimulus remains controversial. By analogy to Apaf-1, it was originally hypothesized that cytochrome c release from the mitochondria might activate Dark. Consistent with this notion were reports demonstrating coprecipitation of Dark with cytochrome c and some capacity for exogenous mammalian cytochrome c to alter Dark sedimentation in gradients (Dorstyn et al., 2002; Kanuka et al., 1999; Rodriguez et al., 1999) . Arguing against a role for cytochrome c in Dark activation, however, other reports have found no detectable cytochrome c release after delivery of an apoptotic stimulus in S2 cells (a D. melanogaster cell line), and lysates prepared from these cells are refractory to the addition of cytochrome c (Dorstyn et al., 2004; Kanuka et al., 1999; Varkey et al., 1999; Zimmermann et al., 2002) . Furthermore, the use of RNA interference to knock down cytochrome c does not appear to alter the progression of apoptosis in D. melanogaster cell lines (Dorstyn et al., 2004; Zimmermann et al., 2002) . Additionally, cytochrome c is not required for the formation of the D. melanogaster double apoptosome, nor does it appear to interact with this complex (Yu et al., 2006) . Given these findings, recent studies from Hermann Steller's group that convincingly demonstrate a role for cytochrome c in caspase activation associated with spermatid differentiation are difficult to place within our current understanding of D. melanogaster apoptosomal function (Arama et al., 2003 (Arama et al., , 2005 . This pathway of spermatid differentiation seems to be dependent upon Dark and Dronc, raising the intriguing possibility that the D. melanogaster apoptosome can be cytochrome c responsive in particular developmental contexts. Alternatively, cytochrome c may have some target other than Dark or Dronc that can act through this pathway. Furthermore, in that knockdown or mutation of the D. melanogaster IAP, DIAP1, is sufficient to induce apoptosis, it may not be necessary to invoke a Dark activator in D. melanogaster apoptosis (Goyal et al., 2000; Lisi et al., 2000; Yoo et al., 2002; Zimmermann et al., 2002) . Indeed, under most, if not all, circumstances, Dark may well have the capacity for constitutive activity in the absence of DIAP1, such that activation of the D. melanogaster apoptosome would simply involve the removal or inactivation of DIAP1.
Physiological Regulation of the Apoptosome
With an increased understanding of apoptosome formation and function has come the recognition that the apoptosome can serve as a distinct locus of apoptotic regulation. Many factors have been discovered that control the efficacy of apoptosome formation and activation under normal physiological conditions (summarized in Table 1 ). In particular, kinase signaling has been shown in a number of settings to affect the activity and formation of the apoptosome, oftentimes through the direct phosphorylation of apoptosomal constituents. The first report of such apoptosomal regulation by phosphorylation came from studies showing that the prosurvival kinase Akt could phosphorylate human caspase-9 on serine 196 and thereby prevent Apaf-1/cytochrome c activation of caspase-9 (Cardone et al., 1998). The universal relevance of this finding has been called into question, however, as the Akt phosphorylation site on caspase-9 was found to be absent even in other mammals (i.e., dog and mouse); hence, the broad significance of Akt-mediated caspase-9 phosphorylation is still not clear (Rodriguez et al., 2000) . Subsequent to these studies, a number of other antiapoptotic kinases have been shown to inhibit caspase-9 by direct phosphorylation. ERK, a member of the MAPK family, inhibits cytochrome c-induced apoptosome activation in cellfree extracts prepared from both Xenopus laevis eggs and mammalian tissue culture cells (Allan et al., 2003; Tashker et al., 2002) . This inhibition appears to result from the direct phosphorylation of caspase-9 by ERK at threonine 125 in mammals (Allan et al., 2003) . Additionally, protein kinase A (PKA) signaling has been shown to alter formation of the apoptosome by preventing the recruitment of caspase-9 to Apaf-1 (Martin et al., 2005) . Although three sites of PKA-mediated caspase-9 phosphorylation have been mapped, mutation of these sites indicates that (in the models tested) they are irrelevant to the prevention of Apaf-1/caspase-9 interactions, suggesting that another PKA substrate is important for apoptosome inhibition. Protein kinase C zeta (PKCzeta), an atypical isoform of PKC that is activated by hyperosmotic stress, has also been demonstrated to phosphorylate caspase-9 (Brady et al., 2005) . This phosphorylation occurs at serine 144 in humans and appears to directly inhibit Apaf-1-mediated activation of caspase-9. In addition to the posttranslational modification of apoptosomal components, there are a variety of proteins that affect the activity of the apoptosome via direct interactions. As described above, XIAP is a direct caspase inhibitor that can bind to and inhibit apoptosomal caspase-9, as well as its downstream target, caspase-3. More specifically, XIAP has been found as a constituent of native apoptosomes, and it can inhibit caspase activation through an interaction with cleaved caspase-9 (Hill et al., 2004; Srinivasula et al., 2001) . The cleavage of caspase-9 bound to Apaf-1 exposes an IAP interaction motif (ATPF in human caspase-9) related to sequences present in other endogenous XIAP binding proteins (i.e., AVPI in Smac).
Additional proteins reported to bind to the apoptosome and inhibit its activity include Aven, Hsp90, Hsp27, Hsp70, HBXIP, TUCAN, and APIP. Although Aven was originally identified in a yeast two-hybrid screen for Bcl-X L interactors (Chau et al., 2000) , it was also found to bind to Apaf-1 and prevent its oligomerization, thus impairing its ability to interact with caspase-9. Hsp70 binding to Apaf-1 prevents the interaction of caspase-9 with Apaf-1, although whether it accomplishes this by affecting Apaf-1 oligomerization is debated (Beere et al., 2000; Saleh et al., 2000) . Additionally, both Hsp90 and APIP have been demonstrated to interact with Apaf-1 and inhibit the interaction between Apaf-1 and caspase-9 (Cho et al., 2004; Pandey et al., 2000) . Interestingly, Hsp27 appears to inhibit the apoptosome through a unique mechanism that involves binding to cytosolic cytochrome c, preventing its interaction with Apaf-1, and subsequently inhibiting the activation of caspase-9 (Bruey et al., 2000) . Another factor, HBXIP, reportedly complexes survivin (an IAP relative) to bind to caspase-9 and inhibit its interaction with Apaf-1 (although neither protein binds to caspase-9 individually) (Marusawa et al., 2003) . TUCAN is a recently identified CARD-containing protein that can complex with caspase-9 and prevent cytochrome c-induced caspase activation (Pathan et al., 2001) . In addition to these apoptosome inhibitors, a recently identified protein termed Nucling has been shown to stably interact with Apaf-1/caspase-9 complexes after cellular stress to promote the translocation of Nucling/Apaf-1/caspase-9 complexes into the nucleus; this relocalization reportedly enhances apoptosome-mediated caspase-9 activation (Sakai et al., 2004) . The protein NAC can also interact with Apaf-1 through a CARD-CARD interaction and can promote the activation of caspases on the apoptosome (Chu et al., 2001) .
Various factors have been found to modulate apoptosomal activity without an apparent direct physical contact with or modification of apoptosomal constituents. The proteins PHAPI and ProT were identified as apoptosomal regulators during a study examining activation of the apoptosome by small molecules (Jiang et al., 2003) . PHAPI (putative HLA-DR-associated protein-1) promotes caspase-9 association with the apoptosome after Apaf-1 oligomerization. In contrast, ProT (prothymosina) inhibits the successful formation of the apoptosome and subsequent caspase activation. Moreover, the RNA binding protein HuR can enhance the antiapoptotic effects of ProT by binding to ProT RNA and enhancing its translation (Lal et al., 2005) . Neither PHAPI nor ProT appears to exert its effects through direct interaction with the apoptosome. Other proteins that indirectly regulate the apoptosome include a-fetoprotein (AFP), which promotes caspase activation by recruiting caspases to the complex (Semenkova et al., 2003) , and acetylcholinesterase (AChE), which appears to promote the interaction between cytochrome c and Apaf-1 (Park et al., 2004) . Furthermore, nitric oxide donors (which modulate cytochrome c activity through nitrosylation as described above) can act directly at the apoptosome to prevent the oligomerization of Apaf-1 and the CARD-CARD interaction between caspase-9 and Apaf-1 (Zech et al., 2003) . Recent efforts aimed at finding small-molecule inhibitors of apoptosis identified diarylurea compounds as inhibitors of Apaf-1 oligomerization and apoptosome formation (Lademann et al., 2003) . Finally, the intracellular concentration of potassium (K + ) may dictate apoptosome activity, as high K + concentrations prevent the oligomerization of Apaf-1 and subsequent incorporation of caspase-9 into the apoptosome, thus inhibiting caspase activation and apoptosis (Cain et al., 2001 ).
Importance of the Apoptosome and Its Regulation during Development
Apoptosomal components play significant roles in normal developmental processes. Apaf-1 null mice display prominent craniofacial and brain abnormalities and exhibit conspicuous lethality by embryonic day 16.5 (Cecconi et al., 1998; Yoshida et al., 1998) . In addition, embryonic stem cells, thymocytes, and fibroblasts derived from these animals are extraordinarily resistant to mitochondria-mediated apoptotic cell death despite the normal release of cytochrome c. Caspase-9 null mice display similar deformities, as they die perinatally with abnormally large brains, caused by a deficiency of normal developmental apoptosis Kuida et al., 1998) . In addition, embryonic stem cells, thymocytes, and embryonic fibroblasts derived from these animals are refractory to apoptotic signals that successfully induce mitochondrial cytochrome c release. Interestingly, Dark hypomorphic flies bearing loss-of-function mutations at the Dark locus exhibit hyperplasia of the central nervous system resulting from reduced developmental programmed cell death, which is highly reminiscent of the phenotypes observed in Apaf-1 null mice (Rodriguez et al., 1999) . Similarly, flies with mutations in the Dark-activated caspase Dronc exhibit supernumerary neurons, and Dark and Dronc mutant flies do exhibit a number of other developmental defects (some overlapping) that may be attributable to defects in programmed cell death (Chew et al., 2004; Daish et al., 2004; Xu et al., 2005) .
To further analyze apoptosome function during murine development, mice devoid of cytochrome c have been generated, and these mice die perinatally by embryonic day 8.5 due to developmental defects (Li et al., 2000) . Cells derived from these mice do show defects in apoptosis, but they also show a significant impairment in cellular respiration, which precluded a complete analysis of cytochrome c function in apoptosis during development. To circumvent this problem, knockin mice were engineered to express a mutant cytochrome c allele with a point mutation rendering it unable to activate Apaf-1, but competent for cellular respiration . These mice also die perinatally with central nervous system defects in a similar time frame to Apaf-1 null and caspase-9 null mice. Fibroblasts derived from these mice are remarkably refractory to apoptosis because they are unable to form active apoptosomes. Interestingly, a previously identified mutation leading to defects in neural tube closure was found to reside in the Apaf-1 gene, resulting in reduced Apaf-1 mRNA and protein and a concomitant decrease in apoptosis (Honarpour et al., 2001) .
The striking brain phenotypes seen in mice bearing knockouts of apoptosomal components highlight the particular importance of the apoptosome in neuronal developmental apoptosis. Despite this requirement for the apoptosome in the establishment of brain architecture during development, neurons undergo a remarkable shift in apoptosome function over the course of development. It was initially found that sympathetic neurons are not readily susceptible to death induced by the introduction of cytochrome c into the cytoplasm (Deshmukh and Johnson, 1998; Neame et al., 1998) . Rather, in response to a particular apoptotic stimulus (e.g., NGF withdrawal), they must acquire ''competence-to-die'' after cytochrome c release. These observations suggested that at least one major regulatory event (besides cytochrome c release) is required for the apoptosis of these cells. This resistance to cytochrome c-induced apoptosis in postmitotic neurons is thought to reflect the need to maintain these cells over the lifetime of the organism.
In sympathetic neurons, competence-to-die can be induced by the introduction of exogenous Smac into the cytosol, suggesting that counteracting the effects of IAPs is critically important in the death of these neurons (Deshmukh et al., 2002) . Indeed, subsequent work has demonstrated that sympathetic neurons from XIAP-deficient mice die very efficiently in response to cytochrome c without additional proapoptotic stimuli (Potts et al., 2003) . A model for understanding this cytochrome c resistance in postmitotic neurons has been established by using PC12 cells, a naive cell line that can be differentiated into mature neurons. These studies have confirmed that postmitotic, neuronally differentiated PC12 cells are remarkably refractory to cytochrome c-induced apoptosis (much like sympathetic neurons drawn directly from the mice) when compared to naive mitotic cells (Vyas et al., 2004; Wright et al., 2004) . This difference in sensitivity to cytochrome c can be attributed to downregulation of Apaf-1 during the process of differentiation, and the resulting loss of apoptosome activity has been postulated to underlie the increased susceptibility of these cells to apoptotic regulation by IAP proteins (Figure 3) . Indeed, it has been demonstrated that Apaf-1 expression decreases during brain maturation in the rat, further validating the above-mentioned findings (Yakovlev et al., 2001 ). Interestingly, more recent studies have demonstrated that another postmitotic cell, the mature cardiomyocyte, is also refractory to cytochrome c-induced apoptosome activation (Potts et al., 2005; Sanchis et al., 2003) .
Outside of the nervous system, analyses of Apaf-1 function have revealed an assortment of developmental roles for the apoptosome. Disruption of the Apaf-1 gene leads to a significant decrease in cell death in the inner ear epithelium and consequent severe morphogenetic defects of the inner ear (Cecconi et al., 2004) . In addition, there is evidence to suggest that appropriate spatiotemporal downregulation of the apoptosome can be critical for developmental events. For example, loss of murine HAND2, a transcription factor required for cardiac, pharyngeal arch, and limb development, leads to embryonic cell death from heart failure that is rescued by loss of Apaf-1 (Aiyer et al., 2005) . These data suggest that HAND2 must oppose the action of Apaf-1 during development, and they imply that the apoptosome must be kept in check at particular times and places for proper development to proceed.
Pathological Regulation of the Apoptosome Apoptosomal Regulation in Cancer
The inhibition of apoptosis has been characterized as a critical hallmark of cancer (Hanahan and Weinberg, 2000) . Thus, it is perhaps not surprising that alterations in apoptosome function have been documented in a number of tumor types (summarized in Table 2 ). Modulation of apoptosome function in cancer was first observed in metastatic melanomas in which Apaf-1 protein was lost due to methylation-induced transcriptional silencing (Soengas et al., 2001 ). Other groups have further characterized and verified apoptosomal inactivation in both melanoma cell lines and tissue samples (Baldi et al., 2004; Dai et al., 2004; Fujimoto et al., 2004a Fujimoto et al., , 2004b Zanon et al., 2004) . As most currently used chemotherapeutic agents kill malignant cells by promoting mitochondrial cytochrome c release, such loss of apoptosome activity likely contributes significantly to chemoresistance in melanomas.
The loss of apoptosome function in tumors does not necessarily reflect alterations in the core apoptosomal component Apaf-1. In the non-small cell lung carcinoma (NSCLC) cell line NCI-H460, dysfunctional apoptosome activity has been attributed to the overexpression of XIAP (Yang et al., 2003) . Accordingly, an XIAP-targeting Smac peptide was able to restore the sensitivity of these cells to cytochrome c-induced apoptosis and act in concert with chemotherapeutic agents (e.g., cisplatin and taxol) to reduce the tumor growth of NCI-H460 xenografts. Other studies of NSCLC have also revealed defects in apoptosome activation in cell lines and tumor tissues despite evidence that various apoptosomal proteins may in fact be upregulated (Krepela et al., 2004 (Krepela et al., , 2006 .
Posttranslational modification of apoptosomal components may also contribute to cytochrome c resistance in malignancies. For example, Bcr-Abl, a constitutively active tyrosine kinase responsible for the pathogenesis of chronic myelogenous leukemia (CML), prevents cytochrome c-induced apoptosome activation by preventing the interaction of pro-caspase-9 with Apaf-1 (Deming et al., 2004) . Preliminary evidence suggests that this impairment in apoptosome formation may be due to phosphorylation of Apaf-1 induced by downstream Bcr-Abl signaling (i.e., not by direct phosphorylation by Bcr-Abl). Defects in apoptosome activation have been demonstrated in other leukemic cell types, but in these cases, cytochrome c resistance stems from a deficiency in Apaf-1 protein (possibly due to methylation of the promoter, as in malignant melanomas) (Fu et al., 2003; Furukawa et al., 2005; Jia et al., 2001 Jia et al., , 2003 .
Other examples of tumors reported to be defective in either apoptosome formation or function include bladder cancers, in which Apaf-1 is downregulated, and glioblastomas, in which LOH-induced Apaf-1 inactivation Reviewhas been observed (Jia et al., 2001; Watanabe et al., 2003) . The loss of Apaf-1 also correlated with aggressive tumor behavior in cervical cancer (Leo et al., 2005) , and in fibrosarcoma cells, both Apaf-1 and caspase-9 are downregulated in a mechanism dependent on the signaling of AMF (autocrine motility factor), a molecule implicated in tumor malignancy (Haga et al., 2003) . Furthermore, despite abundant Apaf-1 expression, ovarian cancer cell lines and tumors have been characterized as having defective apoptosome function, potentially arising from a lack of caspase-9 bound to oligmomerized Apaf-1 (Liu et al., 2002; Wolf et al., 2001 ). Lastly, notwithstanding normal apoptosome function in clear cell RCC (renal cell carcinoma), non-clear cell RCC samples have defects in their responsiveness to cytosolic cytochrome c due to a yet to be determined mechanism (Gerhard et al., 2003) . Recently, a unique mechanism of apoptosomal regulation has been uncovered in one of the most prevalently studied cancers, breast cancer (Figure 4) . By assaying the cytochrome c sensitivity of a panel of breast cancer cell lines, it was found that breast cancer cells are actually exquisitely sensitive to cytochrome c-induced apoptosis when compared to normal mammary epithelial cells (Schafer et al., 2006) . While the malignant mammary epithelial cells displayed evidence of hyperactive apoptosomes, they apparently maintained the requirement of tumor cells for apoptotic inhibition, as they were resistant to chemotherapy-induced cytochrome c release. This unique sensitivity to cytosolic cytochrome c in breast cancer cells appears to be dictated by overexpression of the apoptosomal regulator PHAPI, which was observed in both breast cancer cells and mammary tumors (Schafer et al., 2006) . These findings raise the intriguing possibility that malignant mammary epithelial cells could be killed with reasonable selectivity by the introduction of cytosolic cytochrome c or a chemotherapeutic agent that mimics its action. Indeed, it has been suggested in other studies that stimulating the apoptosome might serve as a means to selectively kill cancer cells (Mashima et al., 2005; Nguyen and Wells, 2003) . That said, downregulation of caspase-3 is observed in some breast cancer cells, so cytochrome c-mimetic therapies would have to be restricted to caspase-3-positive breast cancers (Devarajan et al., 2002) . Apoptosomal Regulation in Other Pathological Conditions Aberrant apoptosome function contributes not only to carcinogenesis, but it has also been implicated in the inappropriate apoptosis characteristic of various degenerative disorders. For example, neural precursor cells (NPCs) lacking Apaf-1 are resistant to a variety of neurodegenerative apoptotic inducers (Cozzolino et al., 2004) . Although proapoptotic stimuli (e.g., amyloid b-peptide) could stimulate cytochrome c release in these cells, the released cytochrome c was degraded by the proteasome when Apaf-1 was absent. Additionally, by using a D. melanogaster model, polyglutamine-induced cell death (characteristic of Huntington's disease) was found to be dramatically suppressed in the absence of the D. melanogaster Apaf-1 homolog, Dark, further suggesting a role for the apoptosome in the pathogenesis of neurodegenerative disorders (Sang et al., 2005) . If apoptosome activity is necessary for the cell death characteristic of neurodegeneration, then inactivation of the apoptosome might provide a therapeutic avenue for treating these disorders. One recently identified Apaf-1-interacting inhibitor, AIP (a splice variant of caspase-9 that is expressed endogenously in the brain), was found to be capable of protecting neurons from cell death Malignant mammary epithelial cells activate caspases more efficiently and robustly after the release of cytochrome c into the cytosol. This is due to the overexpression of PHAPI, which causes enhanced recruitment of caspase-9 to the apoptosome.
induced by cerebral ischemia (Cao et al., 2004) . Accordingly, AIP overproduction has been proposed as a neuroprotective strategy to prevent neurodegeneration as well as stroke-induced neuronal injury.
Inappropriate apoptosome activity has also been shown to play a role in heart disease and in ischemic renal failure. It has long been known that cardiac myocytes are lost to apoptosis during the aging process, contributing to the development of various cardiac disorders. Recently, cytosolic cytochrome c content was found to be elevated in the hearts of 16-and 24-month-old mice when compared to 6-month-old mice, suggesting that changes in cytochrome c-induced apoptosome activation may promote age-related loss of cardiac myocytes (Phaneuf and Leeuwenburgh, 2002) . Of potential therapeutic interest, the amino acid taurine has been shown to limit the apoptosis of cardiomyocytes during myocardial infarction (Takatani et al., 2004) . This protective effect of taurine stems from its ability to prevent the proper formation of the apoptosome by preventing the interaction between caspase-9 and Apaf-1. In the case of kidney disease, the apoptosis of tubular cells has been implicated in the progression of ischemic renal failure. However, a shift to an acidic pH can inhibit the induction of ATP depletion-induced apoptosis in tubular cells by preventing the association of caspase-9 and Apaf-1 (Brooks et al., 2005) . Thus, lowering cellular pH might be an effective means by which to reduce tubular cell apoptosis and the subsequent development of ischemia-induced renal failure.
Conclusions, Perspectives, and Future Directions
Despite recent progress in understanding the role of the apoptosome during development, adult tissue homeostasis, and pathogenesis, a number of questions remain concerning its precise mechanism of activation/formation. For example, we do not yet know the precise binding site of cytochrome c on Apaf-1, nor do we know how dADP is exchanged for dATP after the initial hydrolysis of dATP. The studies of the cytochrome c knockin mice described above have yielded some data that challenge our current understanding of apoptosome function . In contrast to fibroblasts, thymocytes from these animals retain sensitivity to apoptotic stimuli despite the inactivation of cytochrome c. After g-irradiation, caspase activation occurs in the absence of detectable Apaf-1 oligomerization, but in an Apaf-1-dependent manner. This suggests the presence (at least in certain cell types) of a cytochrome c-independent, Apaf-1-dependent mechanism of caspase-9 activation. These findings suggest the possible existence of alternative mechanisms to nucleate an Apaf-1/caspase-9 apoptosome that might bypass a requirement for mitochondria. The existence of mechanisms to inhibit caspase activation at the level of the apoptosome raises the question of whether cells that have been induced to undergo cytochrome c release can survive in the long term after permeablization of their mitochondria. There are conflicting results concerning clonogenic survival after loss of mitochondrial cytochrome c (Ekert et al., 2004; Ricci et al., 2003 Ricci et al., , 2004 Waterhouse et al., 2001 ). It may be true that cells differ in their ability to withstand transient mitochondrial permeablization. In postmitotic neurons, for example, restoration of nerve growth factor after growth factor deprivation allows for long-term survival despite cytochrome c release (Deshmukh et al., 2000) . While this must depend, in part, on the remarkable resistance of mature neurons to cytosolic cytochrome c, it also suggests that mitochondria in these cells can ''recover'' after permeablization. It has been suggested that import of newly synthesized cytochrome c could restore respiratory chain function after mitochondrial repair. Additionally, even nonneuronal cells (which do not necessarily have any resistance to cytosolic cytochrome c) have been reported to maintain mitochondrial respiratory function after the permeablization of the mitochondria by utilizing cytosolic cytochrome c (Waterhouse et al., 2001) .
Emerging evidence that the apoptosome may be altered in various pathological conditions raises the exciting possibility that apoptosome modulators may act as therapeutics. Just as the relative sensitivity of malignant mammary epithelial cells to cytochrome c suggests that cytochrome c mimetics might be effective in breast cancer therapy (Schafer et al., 2006) , the remarkable resistance of postmitotic neurons to cytochrome c raises the possibility that brain tumor cells might be susceptible to similar therapeutic agents (Deshmukh and Johnson, 1998) . The selective induction of apoptosis in tumor cells has been a long-term goal of cancer researchers. The continued study of apoptosomal formation, function, and regulation may soon make the apoptosome a viable therapeutic target not only for cancer treatment, but also for degenerative and developmental disorders.
